Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 1,503 shares, a decline of 87.7% from the May 31st total of 12,174 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 6,655 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of “Hold”.

Get Santen Pharmaceutical alerts:

Read Our Latest Research Report on Santen Pharmaceutical

Santen Pharmaceutical Trading Down 2.6%

SNPHY stock opened at $12.76 on Friday. The stock has a market cap of $4.11 billion and a P/E ratio of 0.10. Santen Pharmaceutical has a twelve month low of $9.22 and a twelve month high of $13.10. The company’s 50 day moving average is $11.55 and its two-hundred day moving average is $11.13.

About Santen Pharmaceutical

(Get Free Report)

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

Read More

• Five stocks we like better than Santen Pharmaceutical
• 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
• 3 Waste Stocks Turning AI Investments into Growth
• 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
• 3 ETFs Pairing Market-Beating Returns With High Dividend Yields

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.